MX2009004339A - Alcoholes de acido graso. - Google Patents

Alcoholes de acido graso.

Info

Publication number
MX2009004339A
MX2009004339A MX2009004339A MX2009004339A MX2009004339A MX 2009004339 A MX2009004339 A MX 2009004339A MX 2009004339 A MX2009004339 A MX 2009004339A MX 2009004339 A MX2009004339 A MX 2009004339A MX 2009004339 A MX2009004339 A MX 2009004339A
Authority
MX
Mexico
Prior art keywords
pro
fatty acid
drugs
acid alcohols
omega
Prior art date
Application number
MX2009004339A
Other languages
English (en)
Spanish (es)
Inventor
Anne Kristin Holmeide
Jenny Rosman
Original Assignee
Pronova Biopharma Norge As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge As filed Critical Pronova Biopharma Norge As
Publication of MX2009004339A publication Critical patent/MX2009004339A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/02Acyclic alcohols with carbon-to-carbon double bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/007Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/24Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with monohydroxylic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
MX2009004339A 2006-11-03 2007-11-02 Alcoholes de acido graso. MX2009004339A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85626806P 2006-11-03 2006-11-03
US85626706P 2006-11-03 2006-11-03
US85626906P 2006-11-03 2006-11-03
SE0602352 2006-11-03
PCT/IB2007/004590 WO2008139261A2 (en) 2006-11-03 2007-11-02 Omega-3 lipid compound

Publications (1)

Publication Number Publication Date
MX2009004339A true MX2009004339A (es) 2009-05-20

Family

ID=39876685

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004339A MX2009004339A (es) 2006-11-03 2007-11-02 Alcoholes de acido graso.

Country Status (10)

Country Link
US (1) US20100266681A1 (enExample)
JP (1) JP2010509204A (enExample)
KR (1) KR20090077081A (enExample)
CN (1) CN101646426A (enExample)
BR (1) BRPI0718393A2 (enExample)
CA (1) CA2667153A1 (enExample)
MX (1) MX2009004339A (enExample)
NO (1) NO20092131L (enExample)
RU (1) RU2009121007A (enExample)
WO (1) WO2008139261A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134147A1 (en) * 2008-05-02 2009-11-05 Pronova Biopharma Norge As Lipid compositions containing derivatives of epa and dha an their use thereof
GB201009368D0 (en) * 2010-06-04 2010-07-21 Sana Pharma As Dietary formulations
US8691297B2 (en) * 2010-09-01 2014-04-08 Nippon Suisan Kaisha, Ltd. Alcoholic injury mitigating agent
CN104582507A (zh) * 2012-06-11 2015-04-29 克利夫兰诊所基金会 心血管疾病和血栓形成的治疗与预防
CN102860506A (zh) * 2012-08-08 2013-01-09 辽宁省大连海洋渔业集团公司 磷虾油微囊粉及其制备方法
PT2961727T (pt) * 2013-02-28 2017-03-08 Pronova Biopharma Norge As Método de preparação do ácido 2-((5z,8z,11z,14z,17z)-icosa 5,8,11,14,17-pentaeniloxi)butanóico
EP2826384A1 (de) 2013-07-16 2015-01-21 Evonik Industries AG Verfahren zur Trocknung von Biomasse
EP3200604B2 (de) 2014-10-02 2025-05-07 Evonik Operations GmbH Verfahren zur herstellung eines futtermittels
BR112017006838B1 (pt) 2014-10-02 2021-07-06 Evonik Operations Gmbh Processo para produzir um alimento para animais compreendendo biomassa contendo pufa, alimento para animais e método para criar animais
US11464244B2 (en) 2014-10-02 2022-10-11 Evonik Operations Gmbh Feedstuff of high abrasion resistance and good stability in water, containing PUFAs
EP3200606B1 (de) 2014-10-02 2021-03-31 Evonik Operations GmbH Verfahren zur herstellung eines pufas enthaltenden futtermittels durch extrusion einer pufas enthaltenden biomasse des typs labyrinthulomycetes

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01207224A (ja) * 1988-02-10 1989-08-21 Nonogawa Shoji:Kk 頭髪用化粧料及び養毛剤
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
ATE384518T1 (de) * 2000-01-31 2008-02-15 Haerting S A Zusammensetzungen enthaltend phytosterol- und policosanolester von fettsäuren zur herabsetzung des cholesterol- und triglyceridspiegels
CN1665566A (zh) * 2000-09-21 2005-09-07 营养21公司 用铬络合物、共轭脂肪酸和 /或共轭脂肪醇治疗糖尿病、减少身体脂肪、改善胰岛素敏感性、缓解高血糖症和高胆固醇血症的方法和组合物
EP1406641B1 (en) * 2001-06-18 2009-01-07 Neptune Technologies & Bioressources Inc. Krill extracts for prevention and/or treatment of cardiovascular diseases
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
BR0309740A (pt) * 2002-05-03 2005-02-22 Pronova Biocare As Uso de ácido eicosapentaenóico (epa), ácido docosaexaenóico (dha) ou de uma mistura de epa e dha ou de um sal ou derivado farmaceuticamente aceitáveis dos mesmos
WO2004018598A1 (ja) * 2002-08-07 2004-03-04 Kao Corporation 油脂組成物
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
WO2004078166A2 (en) * 2003-03-05 2004-09-16 Solvay Pharmaceuticals Gmbh Use of omega-3-fatty acids in the treatment of diabetic patients
SE0303513D0 (sv) * 2003-12-19 2003-12-19 Pronova Biocare As Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof

Also Published As

Publication number Publication date
CA2667153A1 (en) 2008-11-20
WO2008139261A2 (en) 2008-11-20
KR20090077081A (ko) 2009-07-14
CN101646426A (zh) 2010-02-10
US20100266681A1 (en) 2010-10-21
NO20092131L (no) 2009-06-30
BRPI0718393A2 (pt) 2013-11-26
RU2009121007A (ru) 2010-12-10
WO2008139261A9 (en) 2009-11-12
WO2008139261A3 (en) 2009-08-20
JP2010509204A (ja) 2010-03-25

Similar Documents

Publication Publication Date Title
WO2008139261A9 (en) Omega-3 lipid compound
WO2008036353A3 (en) Omega-3 diglyceride emulsions
PL2162019T3 (pl) Kompozycja lipidowa do poprawy czynności mózgu
NZ595599A (en) Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
PH12014502412A1 (en) Use of dpa (n-6) oils in infant formula
MX2010004820A (es) Mezcla lipidica para nutricion infantil.
GB2459809A (en) Fatty acid formulations and methods of use thereof
WO2013170006A3 (en) Oils with anti-inflammatory activity containing natural specialized proresolving mediators and their precursors
NZ709083A (en) Eicosapentaenoic acid (epa) formulations
MX2012005744A (es) Capsulas de principios activos farmaceuticos y esteres de acidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
HK1206248A1 (en) Compositions of statins and omega-3 fatty acids
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
DK1998628T3 (da) Spiselige produkter med et lavt indhold af mættede og trans-umættede fedtstoffer
NZ595204A (en) Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
WO2008129358A3 (en) Oil producing microbes and methods of modification thereof
FR2955459B1 (fr) Composition huileuse riche en monoglycerides de dha
WO2011060944A3 (en) Active pharmaceutical ingredient capsules and polyunsaturated fatty acid esters
EP2257628A4 (en) COMPOSITIONS AND METHODS FOR THE DIFFERENTIAL REGULATION OF THE INSETICITY OF FATTY ACIDS IN MEMBRANLIPIDES AND SEED OIL
MX2010003843A (es) Composicion orodispersable que comprende acidos grasos poliinsaturados sin mal olor ni sabor.
WO2012076363A3 (en) Compositions comprising fatty acyl isethionate surfactant product, alkanoyl compounds and triglycerides with low level of hydrogenation
UA105482C2 (uk) Соняшник з низьким вмістом насичених жирів
MX2011010935A (es) Composicion basada en petrolato comprendido mas de 10%de silicon para sensacion mejorada al tiempo que permanece estable.
WO2009031275A1 (ja) 抗酸化剤
WO2007135518A3 (en) Use of choline-based preparations for the treatment of tinnitus
EP4327870A3 (en) Method for improving white matter integrity in hyperphenylalaninemia and phenylketonuria patients

Legal Events

Date Code Title Description
FA Abandonment or withdrawal